Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

CSR Report Card

Learn About Our Commitment to Patients and Communities in Astellas' Americas 2017 Corporate Social Responsibility Report Card Read More

Astellas Appoints New Head of Diversity and Inclusion

Astellas Appoints New Head of Diversity and Inclusion

Astellas Appoints New Head of Diversity and Inclusion

XOSPATA Approval

XOSPATA Approved

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Learn how we're making strides against a life-threatening cancer in the latest Astellas Way Blog from Percival Barretto-Ko, President, Americas

Learn How We're Making Strides Against a Life-threatening Cancer in the Latest Astellas Way Blog from Percival Barretto-Ko, President, Americas Read More

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration

Astellas US LLC and the Academy of Oncology Nurse & Patient Navigators (AONN+) Announce Collaboration Read More

Bringing Light to the Lives of Cancer Patients

Bringing Light to the Lives of Cancer Patients Read More

1

2

3

4

5

6

News

Latest

News / Media

Dec 14, 2018

Astellas Acquires Potenza Therapeutics - Acquisition adds clinical stage novel immuno-oncology programs to Astellas’ oncology pipeline -

News / Media

Dec 11, 2018

Astellas Launches XOSPATA^® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

News / Media

Dec 04, 2018

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

News / Corporate

Dec 14, 2018

Astellas Acquires Potenza Therapeutics

News / Corporate

Dec 12, 2018

Astellas Promotes Lei Ding to vice president, Payer Strategy, Contracts, and Pricing

News / Corporate

Dec 11, 2018

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation